



VA-IMPACT trial (CSP#2002)

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular Outcomes

WHAT QUESTION ARE WE ASKING?

- **METFORMIN** has been used to treat diabetes for decades, but we are still unsure whether it provides cardiovascular benefit.
- **PRE-DIABETES** is associated with elevated cardiovascular risk.
- We are investigating whether metformin reduces cardiovascular events in patients with established atherosclerosis and pre-diabetes.

INCLUSION CRITERIA

- Established coronary, cerebrovascular, or peripheral arterial disease
- Prediabetes: HbA1c 5.7 to less than 6.5%, and/or fasting blood glucose 100-125 mg/dL



Thank you for supporting VA research!

STUDY PROCEDURES

- Randomization to metformin XR or placebo
- Expected trial duration up to 6 years
- After screening and randomization visits, all follow-up may be conducted by phone
- Lab tests usually every 6 months, in the clinical lab
- Study medication mailed to participants
- Compensation provided to participants

STUDY OUTCOMES AND ORGANIZATION

- Primary outcome: death, MI, stroke, hospitalization for unstable angina, symptom-driven coronary revascularization
- 40 VA sites, 7410 participants

IF YOUR PATIENT MAY QUALIFY, OR FOR MORE INFORMATION, PLEASE CONTACT:

- Punit Goel, MD LSI, 520-792-1450 x16445
- Amani Mikail, Study Coordinator, 520-792-1450 x15519

To confirm that this study is approved or to ask questions about human subjects protections in research, contact the VA Central IRB at 1-877-254-3130. (v2.0 dated 10/01/2021)